Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults

The monoclonal antibody against CTLA-4, Ipilimumab, is a first-in-class immune-checkpoint inhibitor approved for treatment of advanced melanoma in adults but not extensively studied in children. In light of the fact that the immune response early in life differs from that of adults, we have applied...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Arra, Aditya, Pech, Maximilian, Fu, Hang, Lingel, Holger, Braun, Franziska, Beyer, Christian, Spiliopoulou, Myra, Bröker, Barbara M., Lampe, Karen, Arens, Christoph, Vogel, Katrin, Pierau, Mandy, Brunner-Weinzierl, Monika C.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8204976/
https://ncbi.nlm.nih.gov/pubmed/34178430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1938475
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars